The combination of targeted delivery, high photothermal conversion efficiency, and deep-penetrating NIR-II excitation underscores the translational potential of PSMA-OSP12 NPs as a precise and minimally invasive therapeutic strategy for prostate cancer. Here, FOLH1 is linked to prostate carcinoma.